Brofaromine (CGP 11 305 A) in treatment of depression: biological estimation of plasma concentrations.
In an open clinical trial, 13 depressives were treated with the reversible and selective type-A monoamine oxidase (MAO)-inhibitor brofaromine (CGP 11 305 A), the inhibitory potency of deproteinated plasma on a crude MAO preparation from human placenta was measured as a parameter for plasma brofaromine and possibly active metabolites of brofaromine. Patients significantly (p less than 0.01) improved under brofaromine. There were, however, no significant differences in plasma MAO-inhibitory potency between responders (improvement greater than 50%; n = 5) and nonresponders and no correlations with the change from baseline of the total Hamilton Depression Score (HAMD) or with changes of sleep (change from baseline of the HAMD sleep items). MAO-inhibitory potency significantly (p less than 0.05) increased parallel to the increase of the dosage from 50 mg b.i.d. to t.i.d., confirming the validity of this technique. The biological assay applied is a simple and reliable alternative when estimating the plasma concentrations of brofaromine and, possibly, other reversible MAO inhibitors.
Fritze
J
J
Department of Psychiatry and Clinical Neurochemistry, School of Medicine, University of Würzburg, F.R.G.
Becker
T
T
Ziegler
V
V
Laux
G
G
Riederer
P
P
D000328:Adult; D000368:Aged; D003866:Depressive Disorder / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008928:Mitochondria / Q000201:enzymology; D008995:Monoamine Oxidase / Q000378:metabolism; D008996:Monoamine Oxidase Inhibitors / Q000097:blood / Q000627:therapeutic use*; D010880:Piperidines / Q000097:blood / Q000627:therapeutic use*; D010920:Placenta / Q000378:metabolism; D011569:Psychiatric Status Rating Scales
D008996:Monoamine Oxidase Inhibitors; D010880:Piperidines; C038213:brofaromine; D008995:Monoamine Oxidase